SEARCH:   Advanced

Blood, 1 March 2005, Vol. 105, No. 5, pp. 1898-1904. Prepublished online as a Blood First Edition Paper on November 12, 2004; DOI 10.1182/blood-2004-07-2975. This Article Full Text (PDF) All Versions of this Article: 2004-07-2975v1 105/5/1898    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Straathof, K. C Articles by Heslop, H. E Search for Related Content PubMed PubMed Citation Articles by Straathof, K. C Articles by Heslop, H. E Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted August 2, 2004 Accepted November 1, 2004 Treatment of Nasopharyngeal Carcinoma with Epstein-Barr Virus-specific T Lymphocytes Karin C Straathof, Catherine M Bollard, Uday Popat, M H Huls, Teresita Lopez, M C Morriss, Mary V Gresik, Adrian P Gee, Heidi V Russell, Malcolm K Brenner, Cliona M Rooney, and Helen E Heslop* Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA; Department of Pediatrics, Texas Children's Hospital, Houston, TX, USA Department of Medecine, Baylor College of Medicine, Houston, TX, USA Department of Radiology, The Methodist Hospital, Houston, TX, USA Department of Pathology, Baylor College of Medicine, Houston, TX, USA Department of Pediatrics, Texas Children's Hospital, Houston, TX, USA Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA; Department of Pediatrics, Texas Children's Hospital, Houston, TX, USA; Department of Medecine, Baylor College of Medicine, Houston, TX, USA Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA; Department of Pediatrics, Texas Children's Hospital, Houston, TX, USA; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA * Corresponding author; email: hheslop{at}bcm.tmc.edu. Conventional treatment for nasopharyngeal carcinoma (NPC) frequently fails, and is accompanied by severe long-term side effects. Since virtually all undifferentiated NPCs are associated with Epstein Barr virus (EBV), this tumor is an attractive candidate for cellular immunotherapy targeted against tumor-associated viral antigens. We now demonstrate that EBV-specific cytotoxic T cell lines (CTL) can readily be generated from individuals with NPC, notwithstanding the patients' prior exposure to chemotherapy/radiation. Ten patients diagnosed with advanced NPC were treated with autologous CTL. All patients tolerated the CTL, although one developed increased swelling at the site of pre-existing disease. Four patients treated in remission from locally advanced disease remain disease free 19 to 27 months after infusion. Of 6 patients with refractory disease prior to treatment, 2 had complete responses, and remain in remission > 11-23 months after treatment, 1 had a partial remission that persisted for 12 months, 1 has had stable disease for > 14 months and 2 had no response. These results demonstrate that administration of EBV-specific CTL to patients with advanced NPC is feasible, appears to be safe and can be associated with significant anti-tumor activity. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: "T"-ing off on nasopharynx cancer Fred Wang Blood 2005 105: 1841-1842. [Full Text] [PDF] This article has been cited by other articles: A. M. Leen, A. Christin, G. D. Myers, H. Liu, C. R. Cruz, P. J. Hanley, A. A. Kennedy-Nasser, K. S. Leung, A. P. Gee, R. A. Krance, et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation Blood, November 5, 2009; 114(19): 4283 - 4292. [Abstract] [Full Text] [PDF] J. Diekmann, E. Adamopoulou, O. Beck, G. Rauser, S. Lurati, S. Tenzer, H. Einsele, H.-G. Rammensee, H. Schild, and M. S. Topp Processing of Two Latent Membrane Protein 1 MHC Class I Epitopes Requires Tripeptidyl Peptidase II Involvement J. Immunol., August 1, 2009; 183(3): 1587 - 1597. [Abstract] [Full Text] [PDF] K. A. McAulay, T. Haque, G. Urquhart, C. Bellamy, D. Guiretti, and D. H. Crawford Epitope Specificity and Clonality of EBV-Specific CTLs Used to Treat Posttransplant Lymphoproliferative Disease J. Immunol., March 15, 2009; 182(6): 3892 - 3901. [Abstract] [Full Text] [PDF] C. U. Louis, K. Straathof, C. M. Bollard, C. Gerken, M. H. Huls, M. V. Gresik, M.-F. Wu, H. L. Weiss, A. P. Gee, M. K. Brenner, et al. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients Blood, March 12, 2009; 113(11): 2442 - 2450. [Abstract] [Full Text] [PDF] M. H. Fogg, L. J. Wirth, M. Posner, and F. Wang Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma PNAS, March 3, 2009; 106(9): 3318 - 3323. [Abstract] [Full Text] [PDF] J. Klibi, T. Niki, A. Riedel, C. Pioche-Durieu, S. Souquere, E. Rubinstein, S. Le Moulec, J. Guigay, M. Hirashima, F. Guemira, et al. Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells Blood, February 26, 2009; 113(9): 1957 - 1966. [Abstract] [Full Text] [PDF] M. E. Dudley and S. A. Rosenberg Clinical Trials Investigating Adoptive Cell Therapy Combined with Lymphodepletion for Patients with Advanced Cancer ASCO Educational Book, January 1, 2009; 2009(1): 516 - 520. [Abstract] [Full Text] [PDF] C. Quintarelli, G. Dotti, B. De Angelis, V. Hoyos, M. Mims, L. Luciano, H. E. Heslop, C. M. Rooney, F. Pane, and B. Savoldo Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia Blood, September 1, 2008; 112(5): 1876 - 1885. [Abstract] [Full Text] [PDF] K. R.N. Baumforth, A. Birgersdotter, G. M. Reynolds, W. Wei, G. Kapatai, J. R. Flavell, E. Kalk, K. Piper, S. Lee, L. Machado, et al. Expression of the Epstein-Barr Virus-Encoded Epstein-Barr Virus Nuclear Antigen 1 in Hodgkin's Lymphoma Cells Mediates Up-Regulation of CCL20 and the Migration of Regulatory T Cells Am. J. Pathol., July 1, 2008; 173(1): 195 - 204. [Abstract] [Full Text] [PDF] T. A. Haigh, X. Lin, H. Jia, E. P. Hui, A. T. C. Chan, A. B. Rickinson, and G. S. Taylor EBV Latent Membrane Proteins (LMPs) 1 and 2 as Immunotherapeutic Targets: LMP-Specific CD4+ Cytotoxic T Cell Recognition of EBV-Transformed B Cell Lines J. Immunol., February 1, 2008; 180(3): 1643 - 1654. [Abstract] [Full Text] [PDF] M. E. Dudley Warrior, miscreant, suicide: making better killers Blood, October 15, 2007; 110(8): 2781 - 2782. [Full Text] [PDF] C. Quintarelli, J. F. Vera, B. Savoldo, G. M. P. Giordano Attianese, M. Pule, A. E. Foster, H. E. Heslop, C. M. Rooney, M. K. Brenner, and G. Dotti Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes Blood, October 15, 2007; 110(8): 2793 - 2802. [Abstract] [Full Text] [PDF] H. Zhang, K. M. Snyder, M. M. Suhoski, M. V. Maus, V. Kapoor, C. H. June, and C. L. Mackall 4-1BB Is Superior to CD28 Costimulation for Generating CD8+ Cytotoxic Lymphocytes for Adoptive Immunotherapy J. Immunol., October 1, 2007; 179(7): 4910 - 4918. [Abstract] [Full Text] [PDF] S. Landmeier, B. Altvater, S. Pscherer, B. R. Eing, J. Kuehn, C. M. Rooney, H. Juergens, and C. Rossig Gene-Engineered Varicella-Zoster Virus Reactive CD4+ Cytotoxic T Cells Exert Tumor-Specific Effector Function Cancer Res., September 1, 2007; 67(17): 8335 - 8343. [Abstract] [Full Text] [PDF] M. O. Butler, J.-S. Lee, S. Ansen, D. Neuberg, F. S. Hodi, A. P. Murray, L. Drury, A. Berezovskaya, R. C. Mulligan, L. M. Nadler, et al. Long-Lived Antitumor CD8+ Lymphocytes for Adoptive Therapy Generated Using an Artificial Antigen-Presenting Cell Clin. Cancer Res., March 15, 2007; 13(6): 1857 - 1867. [Abstract] [Full Text] [PDF] Y. Ito, A. Demachi-Okamura, R. Ohta, Y. Akatsuka, K. Nishida, K. Tsujimura, Y. Morishima, T. Takahashi, and K. Kuzushima Full-length EBNA1 mRNA-transduced dendritic cells stimulate cytotoxic T lymphocytes recognizing a novel HLA-Cw*0303- and -Cw*0304-restricted epitope on EBNA1-expressing cells J. Gen. Virol., March 1, 2007; 88(3): 770 - 780. [Abstract] [Full Text] [PDF] B. Savoldo, J. A. Goss, M. M. Hammer, L. Zhang, T. Lopez, A. P. Gee, Y.-F. Lin, R. E. Quiros-Tejeira, P. Reinke, S. Schubert, et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs) Blood, November 1, 2006; 108(9): 2942 - 2949. [Abstract] [Full Text] [PDF] C. Smith, L. Cooper, M. Burgess, M. Rist, N. Webb, E. Lambley, J. Tellam, P. Marlton, J. F. Seymour, M. Gandhi, et al. Functional Reversion of Antigen-Specific CD8+ T Cells from Patients with Hodgkin Lymphoma following In Vitro Stimulation with Recombinant Polyepitope J. Immunol., October 1, 2006; 177(7): 4897 - 4906. [Abstract] [Full Text] [PDF] C. W. Tsang, X. Lin, N. H. Gudgeon, G. S. Taylor, H. Jia, E. P. Hui, A. T. C. Chan, C. K. Lin, and A. B. Rickinson CD4+ T-Cell Responses to Epstein-Barr Virus Nuclear Antigen EBNA1 in Chinese Populations Are Highly Focused on Novel C-Terminal Domain-Derived Epitopes. J. Virol., August 1, 2006; 80(16): 8263 - 8266. [Abstract] [Full Text] [PDF] J S Kalpoe, P B Douwes Dekker, J H J M van Krieken, R J Baatenburg de Jong, and A C M Kroes Role of Epstein-Barr virus DNA measurement in plasma in the clinical management of nasopharyngeal carcinoma in a low risk area J. Clin. Pathol., May 1, 2006; 59(5): 537 - 541. [Abstract] [Full Text] [PDF] P. Comoli, P. Pedrazzoli, R. Maccario, S. Basso, O. Carminati, M. Labirio, R. Schiavo, S. Secondino, C. Frasson, C. Perotti, et al. Cell Therapy of Stage IV Nasopharyngeal Carcinoma With Autologous Epstein-Barr Virus-Targeted Cytotoxic T Lymphocytes J. Clin. Oncol., December 10, 2005; 23(35): 8942 - 8949. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020